- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA approves Acanya Gel for the treatment of acne
Author(s):
Redwood City, Calif. ? Arcutis Pharmaceuticals announces the Food and Drug Administration (FDA) approval of Acanya Gel (clindamycin phosphate 1.2 percent and benzoyl peroxide 2.5 percent) for the once-daily treatment of acne vulgaris in patients 12 years and older, according to BusinessWire.
Redwood City, Calif. - Arcutis Pharmaceuticals announces the Food and Drug Administration (FDA) approval of Acanya Gel (clindamycin phosphate 1.2 percent and benzoyl peroxide 2.5 percent) for the once-daily treatment of acne vulgaris in patients ages 12 years and older, according to BusinessWire.
Acanya Gel was evaluated in clinical studies involving more than 3,200 patients with moderate-to-severe acne, and is the only FDA-approved fixed combination antibiotic and benzoyl peroxide medication for the daily treatment of both noninflammatory and inflammatory acne, the company reports.
Adverse reactions to the gel include application site pain (0.1 percent), application site exfoliation (0.1 percent) and application site irritation (0.1 percent). These reactions occurred in less than 0.2 percent of patients, according to the company.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
